A Phase 2 interventional study of Liposomal doxorubicin hydrochloride and Cyclophosphamide in Breast Cancer, sponsored by Cephalon, Inc.. Completed at 22 sites in 6 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-23.
Sponsored by Cephalon, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing liposomal doxorubicin in Breast Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. liposomal doxorubicin · Breast Neoplasms.
Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, this one is the 18th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2008, is one of 37 in phase 2, and was the 31st registered.
14,832 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →5 of the 67 studies testing liposomal doxorubicin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–70
SCRI Development Innovations, LLC · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
Shanghai Pudong Hospital · Sites in China
Ages 18–70 · Women only
National Taiwan University Hospital · Sites in Taiwan
Ages 20+ · Women only
By country, each count listing its studies:
liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 42 · Phase 3 10 · Phase 4 6
First in 2000; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 126 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 57 across the 66 interventional studies. Of the 40 that completed or were terminated, 18 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 67 have an industry lead sponsor. The 10 most frequent:
This study is registered under Cephalon, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Cephalon, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Teva Pharmaceutical Industries, Ltd. has 3 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing liposomal doxorubicin in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03971409Laura Huppert, MD, BAAvelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | 2027-01-31 |
| NCT05748834SCRI Development Innovations, LLCStudy of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of treatment with MYOCET® (doxorubicin hydrochloride) in combination with cyclophosphamide and trastuzumab, 4 cycles, followed by docetaxel plus trastuzumab, 4 cycles, in women with stage II or III breast cancer whose tumour overexpresses the human epidermal growth factor receptor 2 (HER2) gene.
Main Inclusion Criteria:
Main Exclusion Criteria:
The participant:
Note: Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MCH (liposomal doxorubicin hydrochloride \[60 milligrams {mg}/square meter {m\^2}\], cyclophosphamide (600 mg/m\^2), and trastuzumab (8 or 6 mg/kilogram {kg}), administered as intravenous (IV) infusion on Day 1 of each of 4 consecutive 21-day cycles. For the first cycle, the loading dose of trastuzumab will be 8 mg/kg; 6 mg/kg will be used for the remaining cycles. After 4 cycles of MCH, the treatment will be changed to 4 consecutive 21-day cycles of TH (docetaxel \[100 mg/m\^2\] and trastuzumab \[6 mg/kg\]).
Drug: Liposomal doxorubicin hydrochloride · Drug: Cyclophosphamide · Drug: Trastuzumab · Drug: Docetaxel
Participants will receive AC (free doxorubicin hydrochloride \[60 mg/m\^2\] and cyclophosphamide \[600 mg/m\^2\]), administered as IV infusion on Day 1 of each of 4 consecutive 21-day cycles. After 4 cycles of AC, the treatment will be changed to 4 consecutive 21-day cycles of TH (docetaxel \[100 mg/m\^2\] and trastuzumab \[8 or 6 mg/kg\]). For the first cycle, the loading dose of trastuzumab will be 8 mg/kg; 6 mg/kg will be used for the remaining cycles.
Drug: Cyclophosphamide · Drug: Trastuzumab · Drug: Free doxorubicin hydrochloride · Drug: Docetaxel
Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
Also known as: Myocet®
Cyclophosphamide will be administered per dose and schedule specified in the arm description.
Trastuzumab will be administered per dose and schedule specified in the arm description.
Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
Also known as: Anthracycline
Docetaxel will be administered per dose and schedule specified in the arm description.
Percentage of Participants Exhibiting a Pathological Complete Response (pCR) in Breast
The pCR of breast was based upon histologic examination, as confirmed by a central panel of experts, of resected tissue .
Time frame: At the end of Cycle 8 (each cycle length = 21 days)
Percentage of Participants Who Achieved an Objective Response (Complete Response [CR] or Partial Response [PR]), as Defined by World Health Organization (WHO) Guidelines
CR: Disappearance of the lesions and no new lesions. In case of bone metastasis a CR is represented by the normalization of radiography or the complete sclerotic healing of lytic area. PR: In the case of bidimensionally measurable lesions/tumors, a decrease by at least 50% of the sum of the products of the largest perpendicular diameters of each individual lesion/tumor. In the case of unidimensionally measurable lesions a decrease by at least 50% in the largest linear tumour measurement. In the case of non-measurable but evaluable lesions an appreciable change of lesions referable to disease improvement. For bone lesions partial decrease in size or recalcification of lytic areas. No lesion should have progressed and no new lesion should appear.
Time frame: At the end of Cycle 8 (each cycle length = 21 days)
Percentage of Participants With Class III or IV New York Health Association (NYHA) Congestive Heart Failure (CHF)
Occurrence of Class III or IV (NYHA) CHF has been reported. Class III: Participants with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. Class IV: Participants with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.
Time frame: Baseline up to the end of Cycle 8 (each cycle length = 21 days)
Change From Baseline in Left Ventricular Ejection Fraction (LVEF)
The LVEF is a fraction of blood (in percent) pumped out of the left ventricle of the heart (the main pumping chamber). LVEF was measured using multigated acquisition (MUGA) or echocardiography.
Time frame: Baseline, up to 5 years
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. The TEAE was an AE that began or worsened after treatment with study drug. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
Time frame: Baseline up to the end of Cycle 8 (cycle length = 21 days)
Percentage of Participants With Progression or Death
Progression was defined as a 25% or more increase in the size of the lesion or appearance of new lesion. If the participant did not develop an event (disease progression or death), the participant was censored at the last known tumor assessment date (or last follow-up visit without progression documented).
Time frame: Up to 5 Years after randomization
Percentage of Participants Achieving a Pathological Complete Response (pCR) in Breast and Node
The pCR of breast and node was based upon histologic examination, as confirmed by a central panel of experts, of breast tissue resected.
Time frame: At the end of Cycle 8 (each cycle length = 21 days)
Number of Participants Undergoing Breast Conservative Surgery
Time frame: At the end of Cycle 8 (each cycle length = 21 days)
Severity of Adverse Events as Characterized by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
AEs were recorded and graded per the NCI CTCAE scale. The NCI CTCAE is a toxicity scale used to grade the severity of adverse events experienced with cancer treatment. Grade 1= Mild; Grade 2= Moderate; Grade 3= Severe; Grade 4= Life-threatening or disabling; Grade 5= Death related to AE. For summaries for the toxicity grade, participants were counted once at the greatest NCI CTCAE grade.
Time frame: Up to Week 24
| Milestone | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) |
|---|---|---|
| Started | 63 | 63 |
| Received at least 1 dose of study drug | 62 | 63 |
| Completed 8 cycles of treatment | 55 | 56 |
| Completed | 53 | 56 |
| Not completed | 10 | 7 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Disease progression | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Non-compliance to study procedures | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Randomized but not treated | 1 | 0 |
The pCR of breast was based upon histologic examination, as confirmed by a central panel of experts, of resected tissue .
| percentage of participants | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) |
|---|---|---|
| Percentage of Participants Exhibiting a Pathological Complete Response (pCR) in Breast | 41.3 | 54.0 |
CR: Disappearance of the lesions and no new lesions. In case of bone metastasis a CR is represented by the normalization of radiography or the complete sclerotic healing of lytic area. PR: In the case of bidimensionally measurable lesions/tumors, a decrease by at least 50% of the sum of the products of the largest perpendicular diameters of each individual lesion/tumor. In the case of unidimensionally measurable lesions a decrease by at least 50% in the largest linear tumour measurement. In the case of non-measurable but evaluable lesions an appreciable change of lesions referable to disease improvement. For bone lesions partial decrease in size or recalcification of lytic areas. No lesion should have progressed and no new lesion should appear.
| percentage of participants | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) |
|---|---|---|
| Percentage of Participants Who Achieved an Objective Response (Complete Response [CR] or Partial Response [PR]), as Defined by World Health Organization (WHO) Guidelines | 77.8 | 84.1 |
Occurrence of Class III or IV (NYHA) CHF has been reported. Class III: Participants with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. Class IV: Participants with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.
| percentage of participants | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) |
|---|---|---|
| Percentage of Participants With Class III or IV New York Health Association (NYHA) Congestive Heart Failure (CHF) | 0 | 0 |
The LVEF is a fraction of blood (in percent) pumped out of the left ventricle of the heart (the main pumping chamber). LVEF was measured using multigated acquisition (MUGA) or echocardiography.
| percentage of blood pumped out | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) |
|---|---|---|
| Change at Cycle 4 | -1.5 ± 6.5 | -1.0 ± 5.3 |
| Change at Pre-surgery Visit | -0.8 ± 7.1 | -3.4 ± 6.4 |
| Change at Post-surgery Visit | -1.6 ± 7.3 | -3.6 ± 5.7 |
| Change at Month 12 | -0.9 ± 7.0 | -4.4 ± 8.0 |
| Change at Month 24 | 0.6 ± 8.0 | -4.7 ± 7.9 |
| Change at Month 36 | 2.1 ± 5.6 | -3.8 ± 7.4 |
| Change at Month 48 | -1.3 ± 8.3 | -2.5 ± 9.0 |
| Change at Month 60 | -1.0 ± 7.7 | -1.4 ± 11.0 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. The TEAE was an AE that began or worsened after treatment with study drug. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
| Participants | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 62 | 63 |
Progression was defined as a 25% or more increase in the size of the lesion or appearance of new lesion. If the participant did not develop an event (disease progression or death), the participant was censored at the last known tumor assessment date (or last follow-up visit without progression documented).
| percentage of participants | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) |
|---|---|---|
| Participants with progression or death | 11.1 | 12.7 |
| Participants censored | 88.9 | 87.3 |
The pCR of breast and node was based upon histologic examination, as confirmed by a central panel of experts, of breast tissue resected.
| percentage of participants | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) |
|---|---|---|
| Percentage of Participants Achieving a Pathological Complete Response (pCR) in Breast and Node | 38.1 | 47.6 |
| Participants | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) |
|---|---|---|
| Missing data | 7 | 5 |
| Had breast conservative surgery | 33 | 31 |
| Did not have breast conservative surgery | 23 | 27 |
AEs were recorded and graded per the NCI CTCAE scale. The NCI CTCAE is a toxicity scale used to grade the severity of adverse events experienced with cancer treatment. Grade 1= Mild; Grade 2= Moderate; Grade 3= Severe; Grade 4= Life-threatening or disabling; Grade 5= Death related to AE. For summaries for the toxicity grade, participants were counted once at the greatest NCI CTCAE grade.
| Participants | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) |
|---|---|---|
| Grade 1 | 2 | 1 |
| Grade 2 | 9 | 12 |
| Grade 3 | 19 | 18 |
| Grade 4 | 32 | 32 |
| Grade 5 | 0 | 0 |
Collected over Up to 5 years after randomization. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | 0/62 (0%) | 18/62 (29%) | 62/62 (100%) |
| Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) | 4/63 (6.3%) | 21/63 (33.3%) | 63/63 (100%) |
| Event | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 9/62 | 7/63 |
| ConstipationGastrointestinal disorders | 0/62 | 2/63 |
| PyrexiaGeneral disorders | 1/62 | 2/63 |
| LeukopeniaBlood and lymphatic system disorders | 1/62 | 0/63 |
| CyanosisCardiac disorders | 1/62 | 0/63 |
| Vertigo positionalEar and labyrinth disorders | 1/62 | 0/63 |
| AstheniaGeneral disorders | 1/62 | 0/63 |
| FatigueGeneral disorders | 1/62 | 0/63 |
| ErysipelasInfections and infestations | 1/62 | 0/63 |
| Urinary tract infectionInfections and infestations | 1/62 | 0/63 |
| Event | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 41/62 | 46/63 |
| NauseaGastrointestinal disorders | 44/62 | 39/63 |
| AlopeciaSkin and subcutaneous tissue disorders | 37/62 | 41/63 |
| AstheniaGeneral disorders | 28/62 | 36/63 |
| LeukopeniaBlood and lymphatic system disorders | 24/62 | 34/63 |
| Mucosal inflammationGeneral disorders | 32/62 | 25/63 |
| DiarrhoeaGastrointestinal disorders | 27/62 | 25/63 |
| StomatitisGastrointestinal disorders | 21/62 | 21/63 |
| AnaemiaBlood and lymphatic system disorders | 13/62 | 21/63 |
| VomitingGastrointestinal disorders | 17/62 | 21/63 |
The set of enrolled participants included all participants who were randomized to a treatment group, regardless of whether or not a participant received any study drug.
| Age, Continuous(years) | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) | Total |
|---|---|---|---|
| Mean | 48.8 ± 11.6 | 51.1 ± 11.3 | 49.9 ± 11.4 |
| Sex: Female, Male(Participants) | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) | Total |
|---|---|---|---|
| Female | 63 | 63 | 126 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) | Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) | Total |
|---|---|---|---|
| White | 61 | 59 | 120 |
| Black | 0 | 1 | 1 |
| Asian | 1 | 0 | 1 |
| Other | 1 | 3 | 4 |
Ran from Oct 2008 to primary completion in Sep 2015, 83 months.
Results were first posted in Feb 2024, 8 years 5 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 83 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal doxorubicin